

---

# FORM 6-K

## SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

### Report of Foreign Issuer

#### Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

Dated May 30, 2007

## Lorus Therapeutics Inc.

---

(Translation of registrant's name into English)

**2 Meridian Road, Toronto, Ontario M9W 4Z7**

---

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  T

Form 40-F  □

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  □

No  T

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- \_\_\_\_\_

---

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lorus Therapeutics Inc.

Date: May 30, 2007

By: /s/ Elizabeth Williams  
Elizabeth Williams  
Director of Finance and Corporate Secretary

---

**EXHIBIT LIST**

- 99.1 Material Change Report - September 8, 2006
- 99.2 Material Change Report - September 8, 2006
- 99.3 Material Change Report - September 26, 2006
- 99.4 Material Change Report - May 11, 2007

**Form 51-102F3**  
**Material Change Report**

**Item 1 Name and Address of Company**

Lorus Therapeutics Inc. (“**Lorus**”)  
2 Meridian Road  
Toronto, Ontario  
M9W 4Z7

**Item 2 Date of Material Change**

August 30, 2006

**Item 3 News Release**

On August 31, 2006, Lorus issued a press release relating to the material change described below. The press release, a copy of which is attached to this report, was distributed by Canada Newswire.

**Item 4 Summary of Material Change**

Lorus successfully completed the transaction previously announced with High Tech Beteiligungen GmbH & Co. KG (“**High Tech**”) to issue 28.8 million common shares at \$0.36 per share (the “**Purchased Shares**”) for gross proceeds of \$10.4 million, pursuant to a Share Purchase Agreement dated as of July 13, 2006 (the “**Share Purchase Agreement**”).

**Item 5 Full Description of Material Change**

Lorus, a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, successfully completed the transaction previously announced with High Tech to issue the Purchased Shares for gross proceeds of approximately \$10.4 million, pursuant to the Share Purchase Agreement.

Lorus and High Tech also entered into a registration rights agreement that provides, among other things, that High Tech will have a demand right to request, an aggregate number of five times, the registration or qualification of the Purchased Shares for resale in the United States and Canada, subject to certain restrictions. High Tech has also been granted piggy-back rights to enable it to sell the Purchased Shares in connection with a public offering of shares of Lorus, subject to certain exceptions. In addition, pursuant to the Share Purchase Agreement, HighTech will have the right to nominate one nominee on the board of directors of Lorus or, if it does not have a nominee, it will have the right to appoint an observer to the board for as long as it owns shares.

---

In accordance with the terms of the Share Purchase Agreement, Lorus agreed not to issue any common shares or securities convertible into common shares, subject to certain limited exceptions, until July 31, 2007, at a price of less than \$0.36 per common share. In addition, certain named executive officers of Lorus signed "lock-up" agreements whereby they agreed not to dispose of their common shares for a period of 30 days following the closing date, and for the 30 days immediately following such 30 day period, they agreed not to dispose greater than 50% of the aggregate number of common shares they hold as at the closing date.

**Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

**Item 7 Omitted Information**

No information has been omitted on the basis that it is confidential information.

**Item 8 Executive Officer**

The following executive officer of Lorus is knowledgeable about the material change and may be contacted by any of the Securities Commissions in respect of the change:

Name: Jim A. Wright  
Title: President and Chief Executive Officer  
Telephone: (416) 798-1200 (ext. 340)

**Item 9 Date of Report**

September 8, 2006

---

**Attention Business Editors:**

**Lorus Therapeutics completes financing transaction**

-Transaction with High Tech-

TSX: LOR  
AMEX: LRP

TORONTO, CANADA - August 31 /CNW/ - Lorus Therapeutics Inc., a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that it has successfully completed the transaction previously announced with High Tech Beteiligungen GmbH & Co. KG to issue 28.8 million common shares at \$0.36 per share for gross proceeds of \$10.4 million.

**About Lorus**

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in clinical assessment with a pipeline of seven clinical trials in phase II programs, one phase II clinical study completed, and one large Phase III clinical trial recently completed. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin® is a registered trademark of Lorus Therapeutics Inc.

**Forward Looking Statements**

Except for historical information, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information forms, annual reports and 40-F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

---

Lorus Therapeutics Inc.'s recent press releases are available through the Company's Internet site: <http://www.lorusthera.com>.

%SEDAR: 00002368EF

For further information: Lorus Therapeutics Inc., Grace Tse, Corporate Communications, (416) 798-1200 ext. 380, [ir@lorusthera.com](mailto:ir@lorusthera.com) Media Contacts:  
Susana Hsu, Mansfield Communications, (416) 599-0024.

**Form 51-102F3**  
***Material Change Report***

**Item 1 Name and Address of Company**

Lorus Therapeutics Inc. (“**Lorus**”)  
2 Meridian Road  
Toronto, Ontario  
M9W 4Z7

**Item 2 Date of Material Change**

August 31, 2006

**Item 3 News Release**

On September 1, 2006, Lorus issued a press release relating to the material change described below. The press release, a copy of which is attached to this report, was distributed by Canada Newswire.

**Item 4 Summary of Material Change**

Lorus successfully completed the transaction previously announced with Technifund Inc. (“**Technifund**”) to issue, on a private placement basis, 5 million common shares at \$0.36 per share for gross proceeds of \$1.8 million.

**Item 5 Full Description of Material Change**

Lorus successfully completed the transaction previously announced with Technifund Inc. (“**Technifund**”) to issue, on a private placement basis, 5 million common shares at \$0.36 per share for gross proceeds of \$1.8 million.

**Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

**Item 7 Omitted Information**

No information has been omitted on the basis that it is confidential information.

**Item 8 Executive Officer**

The following executive officer of Lorus is knowledgeable about the material change and may be contacted by any of the Securities Commissions in respect of the change:

---



Name: Jim A. Wright  
Title: President and Chief Executive Officer  
Telephone: (416) 798-1200 (ext. 340)

**Item 9 Date of Report**

September 8, 2006

---

**Attention Business Editors:**

**Lorus Therapeutics completes financing transaction**

TSX: LOR  
AMEX: LRP

-Transaction with Technifund-

TORONTO, CANADA - September 1 /CNW/ - Lorus Therapeutics Inc. ("Lorus") a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that it has successfully completed the transaction previously announced with Technifund Inc. to issue, on a private placement basis, 5 million common shares at \$0.36 per share for gross proceeds of \$1.8 million.

**About Lorus**

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has three products in clinical assessment with a pipeline of seven clinical trials in phase II programs, one phase II clinical study completed, and one large Phase III clinical trial recently completed. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin® is a registered trademark of Lorus Therapeutics Inc.

**Forward Looking Statements**

Except for historical information, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information forms, annual reports and 40-F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

---

Lorus Therapeutics Inc.'s recent press releases are available through the Company's Internet site: <http://www.lorusthera.com>.

%SEDAR: 00002368EF

For further information: Lorus Therapeutics Inc., Grace Tse, Corporate Communications, (416) 798-1200 ext. 380, [ir@lorusthera.com](mailto:ir@lorusthera.com) Media  
Contacts: Susana Hsu, Mansfield Communications, (416) 599-0024.

**Form 51-102F3**  
**Material Change Report**

**Item 1 Name and Address of Company**

Lorus Therapeutics Inc. (“Lorus”)  
2 Meridian Road  
Toronto, Ontario  
M9W 4Z7

**Item 2 Date of Material Change**

September 19, 2006

**Item 3 News Release**

On September 19, 2006, Lorus issued two press releases relating to the material changes described below. The press releases, copies of which are attached to this report, were distributed by Canada Newswire.

**Item 4 Summary of Material Change**

Lorus announced that Dr. Jim A. Wright will step down as the President and Chief Executive Officer of Lorus on September 21, 2006 and that Dr. Aiping H. Young will take the position of President and Chief Executive Officer of Lorus on September 21, 2006.

**Item 5 Full Description of Material Change**

Lorus announced that Dr. Jim A. Wright will step down as the President and Chief Executive Officer of Lorus on September 21, 2006 and that Dr. Aiping H. Young will take the position of President and Chief Executive Officer of Lorus on September 21, 2006, the occasion of Lorus’ annual meeting.

**Item 6 Reliance on subsection 7.1(2) or (3) of National Instrument 51-102**

This Report is not being filed on a confidential basis in reliance on subsection 7.1(2) or (3) of National Instrument 51-102.

**Item 7 Omitted Information**

No information has been omitted on the basis that it is confidential information.

---

**Item 8 Executive Officer**

The following executive officer of Lorus is knowledgeable about the material change and may be contacted by any of the Securities Commissions in respect of the change:

Name: Aiping H. Young  
Title: President and Chief Executive Officer  
Telephone: (416) 798-1200 (ext. 379)

**Item 9 Date of Report**

September 26, 2006

---

**Contacts:**

**Lorus Therapeutics Inc. Media Contacts:**

Grace Tse	Susana Hsu
Corporate Communications	Mansfield Communications
(416) 798-1200 ext. 380	(416) 599-0024
Email: ir@lorusthera.com	susana@mcipr.com

**TSX: LOR**

**AMEX: LRP**

**LORUS THERAPEUTICS ANNOUNCES THAT DR. JIM A. WRIGHT WILL STEP  
DOWN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER**

**TORONTO, CANADA - September 19, 2006** - The board of directors of Lorus Therapeutics Inc. ("Lorus") a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announces that Dr. Jim A. Wright will step down as the President and Chief Executive Officer of the Company on September 21, 2006.

Dr. Wright joined the senior management of Lorus in October, 1999, following the merger of Lorus with GeneSense Technologies, a biotechnology company that he co-founded and served as its Chairman of the Board, and President and Chief Scientific Officer. Over the last seven years, Dr. Wright has guided the growth of Lorus from a preclinical research company to an advanced clinical development Company with two recently completed clinical trials, and seven others presently underway. During this time, Lorus has developed a strong diverse pipeline of anticancer products in various stages of development that include antisense, siRNA, immunotherapy, small molecule and tumor suppressor technologies.

Graham Strachan, Chair of the board of directors indicated that, "The Board of Directors wishes to acknowledge and thank Dr. Wright for the very significant contribution that he has made to Lorus' growth and evolution, and also his dedication to the Company and its goals over the years. It is pleased that Dr. Wright has agreed to continue his association with Lorus as a director and will also be available as a special advisor to his successor."

**About Lorus**

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has products in human clinical trials with a pipeline of seven clinical trials in Phase II clinical trial programs, as well as one Phase II and one Phase III clinical trial recently completed. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin® is a registered trademark of Lorus Therapeutics Inc.

---

**Forward Looking Statements**

Except for historical information, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information forms, annual reports and 40-F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s recent press releases are available through the Company's Internet site: <http://www.lorusthera.com>.

---

**Contacts:**

**Lorus Therapeutics Inc. Media Contacts:**

Grace Tse    Susana Hsu  
Corporate Communications    Mansfield Communications  
(416) 798-1200 ext. 380    (416) 599-0024  
Email: ir@lorusthera.com    susana@mcipr.com

**TSX: LOR**

**AMEX: LRP**

**LORUS THERAPEUTICS ANNOUNCES THE APPOINTMENT OF  
A NEW PRESIDENT AND CHIEF EXECUTIVE OFFICER**

**TORONTO, CANADA - September 19, 2006** - The board of directors of Lorus Therapeutics Inc. ("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announces that Dr. Aiping H. Young will take the position of President and Chief Executive Officer of Lorus on September 21, 2006, the occasion of the Company's Annual General Meeting.

Dr. Young has served at various times as Lorus' Vice-President of Research and Development, Chief Technology Officer, and Chief Operating Officer. Previously, Dr. Young was Vice-President of Research for GeneSense Technologies, a biotechnology company that she co-founded, and was a member of its board of directors. Dr. Young has played a key role in the overall development of Lorus and has participated in all phases of Lorus' drug development program and business activities.

Lorus has a diverse anticancer drug development program with seven clinical trials underway, two recently completed, and a variety of novel preclinical products. The Company recently announced that it is focusing on the clinical development of its antisense product, GTI-2040, in the disease related areas of acute myeloid leukemia and myelodysplastic syndrome. Lorus also plans to bring a new small molecule anticancer agent into clinical study.

Graham Strachan, Chair of the board of directors, commented that, "Dr. Young's intimate knowledge of operations is an important asset to the Company as it progresses its research, preclinical, and clinical products towards commercialization. As President and Chief Executive Officer, Dr. Young will be responsible for the development of Lorus' product pipeline, will lead the strategic planning process, and oversee the Company's partnership activities. We are pleased that Dr. Young has accepted her new position in Lorus, and look forward to working with her to achieve the Company's corporate objectives."

---



**About Lorus**

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Late-stage clinical development and marketing may be done in cooperation with strategic pharmaceutical partners. Lorus currently has products in human clinical trials with a pipeline of seven clinical trials in Phase II clinical trial programs, as well as one Phase II and one Phase III clinical trial recently completed. Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP. Virulizin® is a registered trademark of Lorus Therapeutics Inc .

**Forward Looking Statements**

Except for historical information, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties, including, but not limited to, changing market conditions, the Company's ability to obtain patent protection and protect its intellectual property rights, commercialization limitations imposed by intellectual property rights owned or controlled by third parties, intellectual property liability rights and liability claims asserted against the Company, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, product development delays, the Company's ability to attract and retain business partners and key personnel, future levels of government funding, the Company's ability to obtain the capital required for research, operations and marketing and other risks detailed from time-to-time in the Company's ongoing quarterly filings, annual information forms, annual reports and 40-F filings. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Lorus Therapeutics Inc.'s recent press releases are available through the Company's Internet site: <http://www.lorusthera.com>.

## FORM 51-102F3

## MATERIAL CHANGE REPORT

**1. Name and Address of Corporation**

Lorus Therapeutics Inc. (“Lorus” or the “Company”)  
2 Meridian Road  
Toronto, Ontario  
M9W 4Z7 Canada

**Date of Material Change**

May 1, 2007.

**2. News Release**

The press release reporting the material change was issued on May 1, 2007 in Toronto, Ontario via Canada NewsWire Group, a copy of which is attached hereto as Schedule “A”.

**3. Summary of Material Change**

The Company announced on May 1, 2007 that it has signed an agreement with 6707157 Canada Inc. (“Investor”) and an affiliate thereof to recapitalize and reorganize Lorus’ business which, if completed, will result in the addition of approximately \$7.8 million in non-dilutive financing for the Company.

**4. Full Description of Material Change**

The Company announced on May 1, 2007 that it has signed an agreement with 6707157 Canada Inc. and an affiliate thereof to recapitalize and reorganize Lorus’ business which, if completed, will result in the addition of approximately \$7.8 million in non-dilutive financing for the Company.

Under the terms of the agreement, Lorus will transfer all of its assets and liabilities and all of the shares of its subsidiaries held by it to a new company (“Newco”). Current securityholders in Lorus will exchange their securities in Lorus for equivalent securities in Newco (the “Exchange”) and the board of directors and management of Lorus will continue as the board of directors and management of Newco. Newco will change its name to Lorus Therapeutics Inc. and apply for a substitutional listing of the common shares of Newco on both the Toronto Stock Exchange (TSX) and the American Stock Exchange (AMEX). Following the transaction, Newco will continue to carry on the business carried on by Lorus but will have the benefit of the non-dilutive financing.

---

In connection with the transaction and after the Exchange, the share capital of Lorus will be reorganized into voting common shares and non-voting common shares and the Investor will acquire from Newco and the Selling Shareholders (as defined below) approximately 41% of the voting common shares and all of the non-voting common shares by making a cash payment to Newco and the Selling Shareholders equal to approximately \$8.5 million on closing of the transaction less an escrowed amount of \$600,000, subject to certain post-closing adjustments.

In addition to the exchange of securities described above, shareholders who are not residents of the United States will receive voting common shares of Lorus and shareholders who are residents of the United States will receive a nominal cash payment instead of voting common shares. As well, as a condition of the agreement, High Tech Beteiligungen GmbH & Co. KG and certain other shareholders of Lorus (the "Selling Shareholders"), representing approximately 24% of Lorus' issued and outstanding share capital, have agreed to vote in favour of the transaction and to sell to the Investor the voting common shares to be received under the agreement at the same price per share as will be paid to shareholders who are residents of the United States. The directors and officers of Lorus who are security holders have expressed their intention to vote in favour of the transaction.

Current Lorus shareholders, other than residents of the United States and the Selling Shareholders, will receive approximately 59% of the Lorus voting common shares representing, upon completion of the transaction, an economic equity interest of approximately 0.5% of Lorus in addition to their continued equity interest in Newco.

The restructuring will be completed by way of a plan of arrangement and is subject to approval by the Ontario Superior Court of Justice and Lorus' s securityholders in accordance with applicable laws. The transaction is also subject to regulatory approval, including approval of the TSX and AMEX.

Also as a condition of the transaction, the holder of the secured convertible debentures has agreed to vote in favour of the transaction. The Company has agreed to repurchase such holder's outstanding three million common share purchase warrants at a purchase price of \$252,000.

**5. Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**6. Omitted Information**

Not applicable.

---

**7. Executive Officer**

Aiping Young  
President and Chief Executive Officer  
(512) 336-7797

**8. Date of Report**

May 11, 2007.

---

**Schedule A - Press Release**

**LORUS THERAPEUTICS ANNOUNCES REORGANIZATION RESULTING IN  
APPROXIMATELY \$7,800,000 OF NON-DILUTIVE FINANCING**

**TORONTO, CANADA - May 1, 2007** - Lorus Therapeutics Inc. ("Lorus" or the "Company") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that it has signed an agreement with 6707157 Canada Inc. ("Investor") and an affiliate thereof to recapitalize and reorganize Lorus' business which, if completed, will result in the addition of approximately \$7.8 million in non-dilutive financing for the Company. If the transaction is completed, the funds will be used to further advance the Company's product pipeline without diluting the equity interest of its shareholders.

Under the terms of the agreement, Lorus will transfer all of its assets and liabilities and all of the shares of its subsidiaries held by it to a new company ("Newco"). Current securityholders in Lorus will exchange their securities in Lorus for equivalent securities in Newco (the "Exchange") and the board of directors and management of Lorus will continue as the board of directors and management of Newco. Newco will change its name to Lorus Therapeutics Inc. and apply for a substitutional listing of the common shares of Newco on both the Toronto Stock Exchange (TSX) and the American Stock Exchange (AMEX). Following the transaction, Newco will continue to carry on the business carried on by Lorus but will have the benefit of the non-dilutive financing.

In connection with the transaction and after the Exchange, the share capital of Lorus will be reorganized into voting common shares and non-voting common shares and the Investor will acquire from Newco and the Selling Shareholders (as defined below) approximately 41% of the voting common shares and all of the non-voting common shares by making a cash payment to Newco and the Selling Shareholders equal to approximately \$8.5 million on closing of the transaction less an escrowed amount of \$600,000, subject to certain post-closing adjustments.

In addition to the exchange of securities described above, shareholders who are not residents of the United States will receive voting common shares of Lorus and shareholders who are residents of the United States will receive a nominal cash payment instead of voting common shares. As well, as a condition of the agreement, High Tech Beteiligungen GmbH & Co. KG and certain other shareholders of Lorus (the "Selling Shareholders"), representing approximately 24% of Lorus' issued and outstanding share capital, have agreed to vote in favour of the transaction and to sell to the Investor the voting common shares to be received under the agreement at the same price per share as will be paid to shareholders who are residents of the United States. The directors and officers of Lorus who are security holders have expressed their intention to vote in favour of the transaction.

Current Lorus shareholders, other than residents of the United States and the Selling Shareholders, will receive approximately 59% of the Lorus voting common shares representing, upon completion of the transaction, an economic equity interest of approximately 0.5% of Lorus in addition to their continued equity interest in Newco.

---

The restructuring will be completed by way of a plan of arrangement and is subject to approval by the Ontario Superior Court of Justice and Lorus' securityholders in accordance with applicable laws. The transaction is also subject to regulatory approval, including approval of the TSX and AMEX.

Also as a condition of the transaction, the holder of the secured convertible debentures has agreed to vote in favour of the transaction. The Company has agreed to repurchase such holder's outstanding three million common share purchase warrants at a purchase price of \$252,000.

"We are delighted to have entered into these arrangements," commented Dr. Aiping Young, President and CEO of Lorus. "If approved by the securityholders we believe this arrangement will provide Lorus with a significant increase in liquidity without diluting existing securityholders. The additional funds will lessen our dependence on the capital markets and will allow us to accelerate the clinical development of our lead compounds and enhance the development of our drug pipelines. This transaction will not affect Lorus' current shareholder equity interests, or our corporate focus except in a positive way through the additional financing."

#### **About Lorus**

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus has several product candidates in multiple Phase II clinical trials and has completed one Phase II and one Phase III clinical trial. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

#### **Forward looking statements**

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: financings and corporate reorganizations, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance, achievements or the transactions described in this press release to be materially different from any future results, performance, achievements transactions described in this press release, if at all, that may be expressed or implied by such forward-looking statements, including, among others: the progress of negotiations; our ability to obtain regulatory, securityholder and other approvals; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

---

Lorus Therapeutics Inc.'s recent press releases are available through the Company's website at [www.lorusthera.com](http://www.lorusthera.com).

**Enquiries:**

For further information, please contact:

Lorus Therapeutics Inc.

Dr. Saeid Babaei, 1-416-798-1200 ext. 490

[ir@lorusthera.com](mailto:ir@lorusthera.com)